Multiple ACC26 posts report CADENCE phase 2 results that sotatercept reduced pulmonary vascular resistance over 24 weeks in HFpEF patients with combined post- and pre-capillary pulmonary hypertension, a high-risk group with no approved therapies.
CADENCE evaluates #sotatercept in this challenging population with CpcPH-HFpEF
Sotatercept significantly ⤵️ PVR at 24 weeks, demonstrating improved pulmonary hemodynamics
In the CADENCE phase 2 trial of patients with combined pre- and post-capillary pulmonary hypertension, sotatercept reduced pulmonary vascular resistance compared with placebo over a 24-week treatment period.
This finding is one of many signals tracked across Healthcare. The live feed updates every few hours with new expert voices, debates, and emerging ideas.
← Back to Healthcare